Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
EVOK 
Evoke Pharma Inc (EVOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: EVOK (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -65.14% | Avg. Invested days 25 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.04M USD | Price to earnings Ratio - | 1Y Target Price 18 |
Price to earnings Ratio - | 1Y Target Price 18 | ||
Volume (30-day avg) 1 | Beta -0.1 | 52 Weeks Range 1.94 - 9.88 | Updated Date 10/18/2025 |
52 Weeks Range 1.94 - 9.88 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -42.07% | Operating Margin (TTM) -41.55% |
Management Effectiveness
Return on Assets (TTM) -23.67% | Return on Equity (TTM) -152.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 254248 | Price to Sales(TTM) 0.55 |
Enterprise Value 254248 | Price to Sales(TTM) 0.55 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA -0.36 | Shares Outstanding 1558465 | Shares Floating 1390367 |
Shares Outstanding 1558465 | Shares Floating 1390367 | ||
Percent Insiders 1.28 | Percent Institutions 25.39 |
Upturn AI SWOT
Evoke Pharma Inc
Company Overview
History and Background
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. It was founded in 2007. Their initial focus was on developing Gimoti, a nasal spray formulation of metoclopramide for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Core Business Areas
- Pharmaceutical Development and Commercialization: Evoke Pharma focuses on developing and commercializing prescription drugs for gastrointestinal disorders. Their main product is Gimoti.
Leadership and Structure
Matt D'Onofrio serves as the Chief Executive Officer. The company has a board of directors that oversees strategic decisions.
Top Products and Market Share
Key Offerings
- Gimoti: Gimoti is a nasal spray formulation of metoclopramide used to treat diabetic gastroparesis in adults. Market share information is limited due to the competitive landscape, but it is used in patients that are affected by the gastrointestinal disorder. Key competitors include oral metoclopramide and other antiemetics.
Market Dynamics
Industry Overview
The market for gastrointestinal disorder treatments is competitive, with established players and ongoing research into new therapies.
Positioning
Evoke Pharma aims to provide an alternative to oral medications with Gimoti, offering a potential benefit for patients who have difficulty swallowing or absorbing oral drugs. Evoke Pharma is considered a minor player.
Total Addressable Market (TAM)
The gastroparesis market is estimated to be in the hundreds of millions of dollars. Evoke Pharma is positioned to capture a share of this market with Gimoti, but faces challenges in market penetration and acceptance. Estimates suggest $4B TAM for gastroparesis.
Upturn SWOT Analysis
Strengths
- Novel drug delivery method (nasal spray)
- Addresses a specific unmet need in diabetic gastroparesis
- Potential for improved patient compliance compared to oral medications
Weaknesses
- Limited commercialization resources
- Dependence on a single product (Gimoti)
- High marketing costs
- Struggling to penetrate the market.
Opportunities
- Expansion of Gimoti's label to include other indications
- Partnerships with larger pharmaceutical companies for marketing and distribution
- Development of new products to diversify the portfolio
Threats
- Competition from established oral medications and generic alternatives
- Potential for adverse events and safety concerns
- Reimbursement challenges from payers
- Changing regulatory landscape
Competitors and Market Share
Key Competitors
- VRX
- TEVA
- MYL
Competitive Landscape
Evoke Pharma faces significant competition from larger, more established pharmaceutical companies with broader product portfolios and greater resources. Evoke Pharma's competitive advantage lies in Gimoti's unique nasal spray formulation, but it needs to overcome challenges in market access and physician awareness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been slow and challenging due to the limited commercial success of Gimoti.
Future Projections: Future growth is heavily dependent on increasing Gimoti sales and potential new partnerships or label expansions.
Recent Initiatives: Recent initiatives likely focus on increasing awareness of Gimoti and securing reimbursement from payers.
Summary
Evoke Pharma is a small pharmaceutical company with a novel drug delivery system but faces significant challenges in commercializing its product. Gimoti has the potential to address an unmet need in diabetic gastroparesis, but the company needs to overcome competition and secure reimbursement. Future success relies heavily on increasing Gimoti sales, potential partnerships, and sound financial management. Evoke needs to manage cash burn rates and seek financial resources.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is based on limited available information and may not be precise. Financial data is subject to change. Consider consulting a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Evoke Pharma Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2013-09-25 | Co-Founder, CEO & Director Mr. Matthew J. D'Onofrio MBA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 3 | Website https://www.evokepharma.com |
Full time employees 3 | Website https://www.evokepharma.com | ||
Evoke Pharma, Inc. operates as a specialty pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is based in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.